Avalo Therapeutics, Inc.
AVTX
$18.20
$0.201.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -84.74M | -78.26M | -99.88M | -46.22M | 73.01M |
| Total Depreciation and Amortization | 226.00K | 344.00K | 396.00K | 371.00K | 270.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 23.26M | 22.62M | 44.17M | -4.27M | -123.35M |
| Change in Net Operating Assets | 1.57M | 3.84M | 3.05M | 2.69M | -2.25M |
| Cash from Operations | -59.69M | -51.46M | -52.26M | -47.42M | -52.31M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 0.00 | 0.00 | 0.00 |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -56.22M | -81.72M | -84.12M | -70.86M | -- |
| Cash from Investing | -56.22M | -81.72M | -84.12M | -70.86M | 0.00 |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 17.74M | 15.56M | 83.85M | 69.48M | 69.44M |
| Repurchase of Common Stock | -1.29M | -510.00K | -510.00K | -509.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -462.00K | -462.00K | -1.73M | -1.73M | -2.21M |
| Cash from Financing | 15.99M | 14.59M | 81.61M | 67.24M | 67.24M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -99.92M | -118.59M | -54.77M | -51.04M | 14.93M |